Now trading at a price of $37.55, Revolution Medicines has moved -2.2% so far today.
Over the last year, Revolution Medicines logged a -0.3% change, with its stock price reaching a high of $62.4 and a low of $29.17. Over the same period, the stock underperformed the S&P 500 index by -11.4%. AThe company's 50-day average price was $39.42. Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. Based in Redwood City, CA, the Mid-Cap Health Care company has 616 full time employees. Revolution Medicines has not offered a dividend during the last year.
The Firm Has Good EPS Growth:
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue (k) | $50,041 | $42,983 | $29,390 | $35,380 | $11,580 | n/a |
| Net Income (k) | -$47,664 | -$108,159 | -$187,091 | -$248,705 | -$436,367 | -$600,093 |
| Net Interest Expense (k) | $106 | $71 | $12 | n/a | $47,294 | $88,678 |
| Depreciation & Amort. (k) | $2,300 | $2,611 | $3,083 | $3,972 | $1,068 | $6,200 |
| Diluted Shares (k) | 2,772,589 | 54,874 | 72,806 | 80,627 | 113,150 | 167,738 |
| Earnings Per Share | -$22.33 | -$2.01 | -$2.57 | -$3.08 | -$3.86 | -$3.58 |
| EPS Growth | n/a | 91.0% | -27.86% | -19.84% | -25.32% | 7.25% |
| Free Cash Flow (k) | -$52,205 | -$102,997 | -$153,708 | -$235,217 | -$358,301 | -$567,744 |
| CAPEX (k) | $2,589 | $2,933 | $6,528 | $10,816 | $7,729 | $10,308 |
| Current Ratio | 3.11 | 9.63 | 9.77 | 10.65 | 13.06 | 14.2 |
Revolution Medicines does not have a meaningful trailing P/E ratio since its earnings per share are negative. Its forward EPS guidance is negative too, at $-4.05. The average P/E ratio for the Health Care sector is 22.94. The market is placing a fair value on Revolution Medicines's equity, since its P/B ratio of 3.37 is comparable to its sector average of 3.19.
Revolution Medicines Has an Analyst Consensus of Strong Upside Potential:
The 11 analysts following Revolution Medicines have set target prices ranging from $57.0 to $88.0 per share, for an average of $72.91 with a buy rating. The company is trading -48.5% away from its average target price, indicating that there is an analyst consensus of strong upside potential.
Revolution Medicines has an above average percentage of its shares sold short because 10.4% of the company's shares are sold short. Institutions own 106.0% of the company's shares, and the insider ownership rate stands at 1.99%, suggesting a small amount of insider investors. The largest shareholder is Vanguard Group Inc, whose 9% stake in the company is worth $623,781,901.
